- EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies
- Validates clinical value of multi-omics content in organ-specific extracellular vesicles for liver cancer detection
- Data presented at AASLD Liver Meeting, Read more
News
ARTICLES
Mursla Bio’s EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024
Mursla Bio joins leading European consortium to advance clinical applications based on extracellular vesicle science
Mursla Bio was selected to support scaling and commercialization strategy for extracellular vesicle-based disease surveillance and diagnostics
Cambridge, UK, and Boston, MA, USA, 12 November 2024: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to Read more
Mursla Bio enters the US market with strategic expansion
Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients Read more
Mursla Bio presents breakthrough liquid biopsy technology for extracellular vesicles in Cell Press
Novel and scalable analysis of extracellular vesicles sub-types detailed in Cell Press’ iScience Read more
Mursla Bio helps shape the standardisation of EV-based liquid biopsy for clinical use
Mursla Bio participates in a unique global initiative to standardise the clinical use of novel EV-based biomarkers for liquid biopsy Read more
